KMID : 1009020210190030568
|
|
Clinical Psychopharmacology and Neuroscience 2021 Volume.19 No. 3 p.568 ~ p.571
|
|
Lurasidone in Therapy of Treatment-resistant Ultra-rapid Cycling Bipolar Disorder: Case Report
|
|
Siwek Marcin
Gorostowicz Aleksandra
|
|
Abstract
|
|
|
Lurasidone is an atypical antipsychotic approved for the treatment of schizophrenia and bipolar depression. It seems to have a favorable metabolic profile and low risk of causing adverse interactions. Here we present a case of a 25-year old female patient with treatment-resistant ultra-rapid cycling bipolar disorder, obesity, hypothyroidism, and epilepsy. Because of predominant depressive symptoms, occasional occurrence of brief psychotic symptoms and patient¡¯s somatic comorbidities, treatment with lurasidone was initiated. Clinical improvement was observed 3 weeks and cessation of ultra-rapid cycling course of the disease 8 weeks after the beginning of lurasidone treatment. The patient¡¯s level of functioning improved and body mass significantly decreased, with good tolerance of the pharmacotherapy. Lurasidone seems to be a promising treatment option in patients with treatment-resistant rapid cycling bipolar disorder.
|
|
KEYWORD
|
|
Bipolar disorder, Lurasidone hydrochloride, Obesity, Treatment-resistance
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|